2nd INTERNATIONAL SYMPOSIUM ON
INNER EAR THERAPEUTICS

4–6 November 2019
Hanover/Germany
TABLE OF CONTENTS

Organisation and imprint ............................................................... 4
Welcome note ............................................................................... 5
Scientific programme
  Monday, 4 November ............................................................. 6
  Tuesday, 5 November ........................................................... 11
  Wednesday, 6 November ....................................................... 15
Poster presentations ................................................................. 17
Sponsors, exhibitors and media cooperations ................................. 22
Social and cultural programme .................................................. 23
General information ................................................................. 24
General hints for authors and presenters ........................................ 25
Index of speakers, presenting authors and chairs ............................ 26

Design/layout
Layout Krea.tif-art UG (limited liability)
Print Kern GmbH
Circulation 200
Editorial Deadline 18 October 2019

Index
AT = Abstract Talk
P = Poster
ORGANISATION AND ImPRINT

Venue
Medical Park Hanover/Forum Niedersachsen
Feodor-Lynen-Strasse 27
30625 Hanover/Germany

Date
4–6 November

Conference homepage
www.isiet.org

Hosting society
International Society of Inner Ear Therapeutics (ISIET)

Conference chairs
Prof. Prof. h.c. Dr. med Thomas Lenarz
PD Dr. med. Athanasia Warnecke

Department of Otorhinolaryngology
Hanover Medical School (MHH)
Germany

Founding members of the society ISIET
Karen B. Avraham (Tel Aviv/IL)
Bernard Fraysse (Toulouse/FR)
Jeffrey Holt (Boston, MA/US)
Thomas Lenarz (Hannover/DE)
Lawrence R. Lustig (New York, NY/US)
Christine Petit (Paris/FR)
Abdelaziz Raji (Marrakesh/MA)
Saaid Safieddine (Paris/FR)
Anne G. M. Schilder (London/GB)
Lei Song (Shanghai/CN)
Hinrich Staecker (Kansas City, KS/US)
Hao Wu (Shanghai/CN)
Fondation Pour l’Audition (Paris/FR)

Professional congress organiser
Conventus Congressmanagement & Marketing GmbH
Juliane Meißner & Nora Schambach & Oliver Ong
Phone +49 3641 31 16-318
isiet@conventus.de l www.conventus.de
Dear friends and colleagues,

The International Society of Inner Ear Therapeutics (ISIET) is a global non-profit interdisciplinary organization for scientists and physicians related to inner ear therapeutics covering the complementary range from translational science to clinical applications. ISIET is a young society with an already large number of renown multinational members composed of basic and clinical scientists. Being mainly founded by members of academic institutions, device companies and new or emerging pharmacological and biotechnological industries are attracted by ISIET.

Our mission is to provide a global platform and network for the dissemination and exchange of expertise on different novel treatment modalities of inner ear-related diseases. Mainly otological therapeutics ranging from gene therapy, cell-based approaches, novel drugs and regenerative strategies as well as translational aspects are covered.

After a very successful first conference in Marrakech 2017, the second conference unites academia and industry at the forefront of scientific and medical advancement related to inner ear therapeutics for a strategic targeting of challenges thereby accelerating clinical translation. The agenda is rich in inspirational presentations that we hope will stimulate productive and influential discussions. It provides an excellent opportunity to be part of a unique stage for an in-depth dialogue between world leading experts from universities, societies and biotech companies.

We therefore cordially welcome you to Hanover, the home of the scientist and philosopher Gottfried Wilhelm Leibniz.

On behalf of the founding members of the society,

Prof. Prof. h.c. Dr. med.
Thomas Lenarz

PD Dr. med.
Athanasia Warnecke
8:15–10:00 Introduction, welcome note and keynote lectures
   Chairs T. Lenarz (Hanover/DE) A. Warnecke (Hanover/DE)

8:30 State of the art – inner ear therapies: Where we are
   T. Lenarz (Hanover/DE)

8:45 Keynote 1 – Microcirculatory disorders as a basic initiator of degenerative disease
   A. Haverich (Hanover/DE)

9:20 Keynote 2 – Adeno Associated Virus (AVV) vectors – how to optimize a smart virus for in vivo gene therapy
   H. Büning (Hanover/DE)

10:00–10:30 Break

10:30–11:45 Session 1
   Proteomics, biomarkers and neuroinflammation
   Chairs A. Szczepak (Berlin/DE) A. Warnecke (Hanover/DE)

10:30 AT1
   TLR4 and MyD88 activation of TRPV1 modulates cellular uptake of aminoglycosides
   F. Taghizadeh, M. Jiang, W. Meier (Portland, OR/US), P. Steyger (Omaha, NE/US, Portland, OR/US)

10:45 Keynote 3A – EVs as novel translational inner ear therapeutics
   E. Rohde (Salzburg/AT)

11:15 Keynote 3B – Manufacturing aspects for cell based-therapeutics
   M. Gimona (Salzburg/AT)

11:45–12:45 Lunch
12:45–13:50  Session 2
Clinical genetics

Chairs
S. Saffieddine (Paris/FR)
V. van Rompaey (Antwerpen/BE)

12:45  Highlight talk – Progressive adult-onset sensorineural hearing loss: challenges and opportunities for innovative therapies
V. van Rompaey (Antwerpen/BE)

13:15  Clinical genetics on “presbycusis genetics landscape”
C. Petit (Paris/FR)

13:35  AT2
ACSL4 mutation leads to early and fast progressive hearing loss in mice

13:50–15:15  Session 3
Neurotrophins, small molecules and modes of delivery

Chairs
M. Knipper (Tübingen/DE)
T. Thum (Hanover/DE)

13:50  Keynote 4 – Small molecules clinical trial for Menière’s disease
J. Kil (Seattle, WA/US)

14:30  Highlight talk – LncRNA as novel therapeutic targets
T. Thum (Hanover/DE)

15:00  AT3
Engraftment of human pluripotent stem cell-derived otic progenitors in the damaged adult cochlea
A. Zine (Montpellier/FR), A. Lopez-Juarez (Guanajuato/MX), H. Lahlou (Boston, MA/US), C. Ripoll (Montpellier/FR), A. Edge (Boston, MA/US)

15:15–15:45  Break
15:45–17:00 Session 4
Cohorts and biobanking

Chairs
A. Lesinski-Schiedat (Hanover/DE)
T. Illig (Hanover/DE)

15:45 AT9
Developing precision medicine for sensorineural hearing loss – learning from existing cohorts
C. Santos, A. G. M. Schilder (London/GB)

16:00 AT5
Can we develop a national comprehensive cohort of patients with hearing loss?
N. Mehta, A. G. M. Schilder (London/GB)

16:15 AT6
Genotype phenotype studies are important for the evaluation of molecular inner ear therapies
H. Yntema (Nijmegen/NL)

16:30 AT8
Prognostic factors for outcomes of idiopathic sudden onset sensorineural hearing loss:
the SeaSHeL UK prospective cohort study
R. Mandavia, SeaSHeL Collaborative (London/GB)

16:45 AT4
Clinical next generation sequencing database of deafness – unified management tool of clinical and
genetic information
S. Y. Nishio, S. I. Usami (Matsumoto/JP)
17:00–18:30 Session 5
Local drug-delivery

Chairs
N. Prenzler (Hanover/DE)
F. F. Telischi (Miami, FL/US)

17:00 AT28 former P8
In vivo assessment of dexamethasone (DXM) infused and coated poly(lactic-co-glycolic acid) (PLGA) microneedles as an improved drug delivery system for intracochlear biodegradable devices
D. Pawley, S. Goncalves, E. Bas, E. Dikici, S. Deo, S. Daunert, F. F. Telischi (Miami, FL/US)

17:15 AT29 former P1
Local drug delivery based on a particulate chitosan gel: a preclinical study
G. Laurell, P. Videhult Pierre, P. Damberg, M. Kisiel (Uppsala/SE), S. Nikkhou Aski, (Stockholm/SE), M. Andersson (Södertälje/SE), L. Häggren (Södertälje/SE), A. Fransson (Stockholm/SE)

17:30 AT30 former P5
Targeted delivery of drugs to the otic compartment: preclinical and clinical experience
F. Piu, X. Wang, R. Fernandez, N. Tsivkovskaia, S. Coleman, T. Altmann, J. Hou (San Diego, CA/US)

17:45 AT31 former P2
Long-term effects and potential limits of intratympanic dexamethasone-loaded hydrogels combined with dexamethasone-eluting cochlear electrodes in a guinea pig model
N. Ahmadi, J. C. Gausterer, C. Honeder, C. Arnoldner (Vienna/AT)

18:00 AT32 former P9
Silicone matrices for controlled drug delivery to the inner ear – effects of combining dexamethasone and dexamethasone sodium phosphate
A. Qnouch, V. Solarczyk, J. Verin, C. Vincent, F. Siepmann, J. Siepmann (Lille/FR)
18:15  FX-322, a cochlear progenitor cell activator as a potential therapy for sensorineural hearing loss
       C. LeBel, W. McLean (Woburn, MA/US)

18:30–20:00  Welcome reception at posters

20:30  Speakers’ dinner (on invitation only)
       at the restaurant “Agorino”
       Berckhusenstrasse 31, 30625 Hanover
8:30–10:00  Session 6
miRNA and epigenetics
Chairs K. B. Avraham (Tel Aviv/IL)
H. Staecker (Kansas City, KS/US)

8:30  Keynote 5 – Stem cell-derived organoids as a humanized model for congenital inner ear disorders
E. Hashino (Indianapolis, IN/US)

9:10  Highlight talk – Gene electrotransfer via the cochlear implant electrode
G. Housley (Sydney/AU)

9:40  AT10
The orchestration of hearing – the epigenetic landscape of the inner ear
K. B. Avraham (Tel Aviv/IL)

10:00–11:00  Break at posters

11:00–12:15  Session 7
Bionic and biohybrid devices
Chairs T. Lenarz, (Hanover/DE)
A. Raji (Marrakech/MA)

11:00  Highlight talk – Clinical approaches for improved wound healing
E. Lewis (Beersheba/IL)

11:30  AT11
Cochlear optogenetics by ultrafast optogenetic stimulation of the auditory pathway
V. Rankovic, D. Keppeler, B. Bal, D. Lopez de la Morena, T. Mager, A. Huet, T. Moser (Göttingen/DE)

11:45  AT12
The improvement of the human hearing capacity with Low Level Laser Therapy (LLLT) – a look back over 25 years of clinical experiences
L. Wilden (Jesus, Ibiza/ES)
12:00 AT13
Reproducible and long term efficacy of a new neuromodulation treatment for tinnitus evaluated in over 500 participants
B. Langguth (Regensburg/DE), C. Hamilton, S. Hughes, E. Meade (Dublin/IR), M. Schecklmann (Regensburg/DE), T. Subramaniam (Dublin/IR), S. Vanneste (Dublin/IR, Dallas, TX/US), D. Hall (Nottingham/GB), B. Conlon (Dublin/IR), H. Lim (Minneapolis, MN/US, Dublin/IR)

12:15–13:15 Lunch

13:15–15:30 Session 8
Gene therapy
Chairs L. R. Lustig (New York, NY/US)
J. Holt (Boston, MA/US)
H. Büning (Hanover/DE)

13:15 Keynote 6 – Lentiviral vectors: A large capacity vectorization approach to the inner ear?
A. Schambach (Hanover/DE)

13:45 Keynote 7 – Genome editing – how far from clinics
Z.-Y. Chen (Boston, MA/US)

14:15 AT14
CRISPR/Cas9-mediated targeted Y chromosome elimination in the mammalian auditory system
Y. Tao, H. Wu, X. Zhao, Z. Sun, T. Dong (Shanghai/CN)

14:30 AT15
Exploring regulatory networks of miR-96 to identify therapeutic targets for progressive hearing loss
M. Lewis, M. A. Moreno Pelayo, K. Steel (London/GB)

14:45 AT16
Development of a mutant-allele specific genetic therapy for DFNA9
E. de Vrieze, J. Peijnenborg, H. Kremer, E. van Wijk (Nijmegen/NL)
15:00 AT17
Gene therapy rescues inner hair cell synaptic function and hearing in synaptosomal-associated protein-25 deficient mice

15:15 AT 34 former P17
Template-free genome editing profiles are biased in postmitotic hair cells
L. Liu, W. Xiong (Beijing/CN)

15:30–16:00 Break at posters

16:00–16:45 Session 8
Gene therapy (continued)
Chairs B. Mazurek (Berlin/DE) 
L. Song (Shanghai/CN)

16:00 Highlight talk – Epigenetics of development and the failure of regeneration in the mammalian inner ear
N. Segil (Los Angeles CA/US)

16:30 AT27
Tailored AAV-based transgene expression in the inner ear with cell-type specific promoters
16:45–17:45 Session 9
Site of lesion diagnostics and in vivo imaging
Chairs B. Mazurek (Berlin/DE)
L. Song (Shanghai/CN)

16:45 AT19
The need for a deep phenotype of hearing loss to guide inner ear therapy – understanding speech-in-noise and the underlying site-of-lesion
C. Lanting (Nijmegen/NL), J. Leijendekkers (Zwolle/NL), A. Bosman, A. Snik, R. Pennings (Nijmegen/NL)

17:00 AT20
Effects of cochlear implantation on microvascular permeability in the cochlear lateral wall
B. P. Ernst, S. Siemer, D. Wünsch, U. R. Heinrich, R. H. Stauber, S. Strieth (Mainz/DE)

17:15 AT21
Effects of local cochlear lesions at peripheral dendrites or somata of spiral ganglion neurons on electrophysiological markers
W. Konerding (Hanover/DE), J. Arenberg (Boston, MA/US), A. Kral, P. Baumhoff (Hanover/DE)

17:30 AT33 former P3
Interest of cochlear transparency associated with confocal laser scanning microscopy and light sheet microscopy for three-dimensional cochlear visualization and tissue damage after implantation
P. E. Lemesre, M. Risoud, M. Tardivel, J. Siepmann, C. Vincent (Lille/FR)

17:45–19:00 ISIET board meeting (founding members only)

20:00 Social evening
at the restaurant “Meiers Lebenslust”
Osterstrasse 64, 30159 Hanover
8:30–10:25  Session 10  
Cell-based approaches including regeneration  
Chairs  
Y.-C. Hsu (Taipei/TW)  
A. Schambach (Hanover/DE)  

8:30  Keynote 6 – The fast and the curious: high-throughput in vitro and in vivo interrogation of AAV capsid libraries  
D. Grimm (Heidelberg/DE)  

9:10  Highlight talk – Local drug delivery: application modes and clinical feasibility  
S. Plontke (Halle/DE)  

9:40  AT22  
Combined BDNF and NT-3 growth factor treatment boosts neurite outgrowth in an adult like postnatal day 7 murine in vitro spiral ganglion explant model  
H. Löwenheim, M. Müller, S. Fink (Tübingen/DE)  

9:55  AT23  
CRISPR-on system for the activation of endogenous human ATOH1, POU4F3, SOX2 and inner ear genes: bases for a possible cell replacement therapy in hearing loss  
G. Perez Raffo, L. Vigezzi, C. Fagundez, C. Giménez, C. Boccio, F. Pereyra-Bonnet (Buenos Aires/AR)  

10:10  AT24  
Application of mesenchymal stem cells and extracellular vesicles in restoring the cisplatin-induced hearing loss and rescuing the loss of cochlear hair cells in mice  
Y. C. Hsu (Taipei/TW)  

10:25–11:00  Break at posters
11:00–12:35  Session 11  
Outcome measures and clinical trials

Chairs  
A. G. M. Schilder (London/GB)  
R. Salcher* (Hanover/DE)

11:00  Highlight talk – Protection from cisplatin toxicity  
K. Rajput (London/GB)

11:30  Trials, training, networks in inner ear therapeutics: Where do we go from here?  
A. G. M. Schilder (London/GB)

11:50  AT25  
Oral SENS-401 reduces central auditory neuronal loss after acoustic trauma in NMRI mice  
S. Voigt, M. Gröschel, D. Basta, A. Ernst (Berlin/DE), J. Dyhrfjeld-Johnsen (Montpellier/FR)

12:05  AT26  
Development of ORC-13661 – a medicine to prevent aminoglycoside-induced ototoxicity  
D. Raible, E. Rubel, J. Simon, V. Groppi, G. Johnson, M. Gleser (Seattle, WA/US)

12:20  State of the art – inner ear therapies: Where will we go  
A. Warnecke (Hanover/DE)

12:35  Farewell

14:00–16:00  Post conference tour (for those who are interested, registration requested)

INNER EAR LABS – guided tour through NIFE  
(Lower Saxony Centre for Biomedical Engineering, Implant Research and Development)

*Requested at state of printing.
Posters need to be mounted from Monday 10:00 until Wednesday 11:00. Presenting authors are politely asked to stay nearby their posters during welcome reception and the breaks at posters.

**Local drug delivery**

**P4**
Dexamethasone-loaded ear cubes do not protect Mongolian gerbil against acoustic trauma  

**P6**
Local delivery of therapeutics to the inner ear – the state of the science  
C. Xie, C. Anderson, M. Su, M. Garcia, H. Blackshaw, A. G. M. Schilder (London/GB)

**P37**
Fiber-based neuronal guidance scaffold  
I. Wille*, J. Schulze, A. Warnecke*, P. Behrens* (Hanover/DE), *Cluster of Excellence Hearing4all, German Research Foundation

**P40**
Development of a culture chamber for testing drug delivery strategies to the inner ear for a guided neurite outgrowth  
V. Scheper*, A. Frisch, T. Lenarz*, S. Hügl*, J. Schwieger (Hanover/DE), *Cluster of Excellence Hearing4all, German Research Foundation

**P41**
Intracochlear drug delivery using the cochlear catheter  
N. Prenzler (Hanover/DE)

**Antioxidants, Anti-apoptose**

**P10**
Intratympanic poloxamer 407 increases perilymph concentrations of N-acetylcysteine  

**P11**
Dysregulation of redox homeostasis as therapeutic target in animal models of acquired sensorineural hearing loss  
A. R. Fetoni, F. Paciello, R. Rolesi, D. Troiani, G. Paludetti (Rome/IT)
P12
Comparative efficacies of antioxidant treatments against cisplatin in the Wistar rat model

P13
Anti-apoptotic effect of melatonin in case of ototoxic hearing loss
V. Korotkova, N. Petrova, E. Petrova, R. Ambartsumyan (St. Petersburg/RU)

P14
Repurposing an FDA-approved drug dabrafenib for protection from noise- and cisplatin-induced hearing loss
M. A. Ingersoll, L. E. Caster, E. M. Holland, J. DiGuiseppi, Z. Xu, H. Feng (Omaha, NE/United States), D. Currier, J. Min, T. Chen (Memphis, TN/United States), J. Zuo, T. Teitz (Omaha, NE/US)

Gene therapy
P15
Screened AAV variants permit efficient transduction access to supporting cells and hair cells for gene therapy
J. Wang, X. Hu, H. Yang, H. Li, Y. Shu (Shanghai/CN)

P16
AAV2.7m8 is a powerful viral vector for inner ear gene therapy

P36 former AT18
AAV gene therapy rescues hearing in a mouse model of SYNE4 deafness
S. Taiber (Tel-Aviv/IL), Y. Asai (Boston, MA/US), O. Yizhar-Barnea (Tel-Aviv/IL), J. R. Holt (Boston, MA/US), K. B. Avraham (Tel-Aviv/IL)

Cell-based approaches
P18
The efficacy and safety of Wnt and Notch-signaling modulators in the cochlea
R. Yadak, F. G.J. Hendriksen, D. Ramekers, H. Versnel, R. J. Stokroos, L. V. Straatman (Utrecht/NL)
P19
Transplantation of human pluripotent stem cell-derived cells into the selectively ablated mouse organ of Corti
S. Gubbels, H. Takeda, A. Dondzillo (Aurora, IL/US)

P39
Mesenchymal stem cell effects on the noise damaged inner ear: an RNAseq analysis of protective pathways
J. Schulze (Hanover/DE), M. Shew (Kansas, KS/US), A. Warnecke (Hanover/DE), A. J. Mellott (Kansas, KS/US), T. Lenarz (Hanover/DE), H. Staecker (Kansas, KS/US)

Various
P21
Recruitment to a Phase I/II inner ear therapeutic trial – What have we learned?

P22
The PATH study: preparing for the adoption of novel therapeutics in hearing loss – an early health economic model

P23
Translational Hearing Center at Creighton University, Omaha, Nebraska
P. Steyger, J. Zuo (Omaha, NE/United States)

P25
Cost-effectiveness of contrast-enhanced magnetic resonance imaging for screening retro-cochlear pathologies in unilateral hearing loss
F. Ardıç, F. Tümkaya, P. Çaknak, E. Mengi, M. Şentürk, C. Kara (Denizli/TR)

P26
Neuritin restores auditory processing following SGNs cochlear denervation of Mongolian gerbils
F. Gui, H. Wang, X. Song, X. Sun, Y. Hong, Y. Yang, R. Chen, L. Yang (Hangzhou/CN)
P28
Protection of the auditory nerve following gelfoam-mediated neurotrophic treatment in deafened guinea pigs
H. Vink, D. Ramekers, H. Thomeer, H. Versnel (Utrecht/NL)

P29
Targeted single-cell electroporation loading of Ca\(^{2+}\) indicators in the mature hemicochlea preparation
T. Zelles, E. Berekméri, O. Deák, T. Téglás, T. Sághy, T. Horváth, M. Aller (Budapest/HU), T. Fekete (Toronto/CA), L. Köles (Budapest/HU)

P31
Optogenetic cochlea stimulation for hearing restoration near physiological spectral selectivity
C. Wrobel, A. Dieter, M. Jeschke, G. Hoch, T. Moser (Göttingen/DE)

P33
Recovery from sudden unilateral low frequency sensorineural hearing loss – a case study
D. Raumane, P. Stradiņš (Riga/LV)

P34
A meta analysis on repetitive transcranial magnetic stimulation (RTMS) as treatment for chronic tinnitus
D. B. B. Fuentes, N. A. Almazan (Quezon City/PH)

P35
Influence of omega-3 fatty acids and L-carnitine on the metabolic activity of the human neuroblastoma (SH-SY5Y) and the mouse organ of Corti (HEI-OC1) cell lines
W. Nuss, G. Brandes, A. Warnecke, M. Teschner, T. Lenarz, K. Wissel (Hanover/DE)

P38
Human but not mouse Comentin protects rat primary auditory neurons from degeneration in vitro
J. Schwieger (Hanover/DE), K. A. Petersen (Copenhagen/DK), T. Lenarz*, V. Scheper* (Hanover/DE)
*Cluster of Excellence Hearing4all, German Research Foundation
For the award of the poster prize the following way of action is planned:

1st prize is endowed with 1,500 EUR: Poster for translational research, for infrastructure or next generation inner ear therapy.

2nd and 3rd prizes are endowed with 750 EUR each: New therapeutic approaches. Here, translational as well as experimental approaches will be considered.

All posters will be mounted during the whole 2.5 days of the conference.

Selection process:
1. Preselection through participants:

Every participant will receive three labels and places these three on his top three posters during the welcome reception on Monday evening. The evaluation will be executed on Tuesday morning by the ISIET organising team. This result states a first ranking regarding quality.

The ISIET organising team assigns three posters each to the categories translational resarch, infrastructure for next generation inner ear therapy and experimental approaches.

2. Selection through the ISIET founding members:
On Tuesday afternoon the ISIET organising team presents the three posters of each category to the the ISIET founding members – followed by a vote by hand which determines the poster prize winners.

The announcement of the poster prize winners as well as the handover takes place during the social evening. (If poster prize winners cannot be present on the social evening, the handover will take place during the farewell session).

With friendly support of Acousia Therapeutics GmbH
Sponsor of the ISIET Poster Prize 2019
SPONSORS, EXHIBITORS AND MEDIA COOPERATIONS

Sponsors and exhibitors

- Acousia Therapeutics GmbH
- Advanced Bionics GmbH
- CILcare SAS
- COCHLEAR Deutschland GmbH & Co. KG
- Decibel Therapeutics
- Frequency Therapeutics, CT
- Hearing Medicines Discovery Syndicate
- Med-EI Eletromedicinische Geräte GmbH
- Neuromod Devices Ltd
- Oticon GmbH
- Rescue Hearing Inc.
- Sensorion SA

Media cooperations

- Median-Verlag von Killisch-Horn GmbH
- Zeitschrift für Audiologie
- pinpoint Scotland ltd.
- ENT & audiology news
- Springer Verlag GmbH
- European Archives of Oto-Rhino-Laryngology and Head & Neck
- S. Karger AG
- Journal for Oto-Rhino-Laryngology, Head and Neck Surgery (ORL)

State at printing
Scientific networking – Welcome reception at posters
Right after the round table discussions we would like to invite you to our scientific networking with welcome reception within the poster exhibition. Be our guest and round the evening in a relaxed and communicative atmosphere and meet your colleagues, as well as friends. Furthermore you can take part in the pre-selection process of the poster prize. (please see p. 21 for detailed information).

Date: Monday, 4 November
Time: from 18:30
Place: Medical Park Hanover
(venue of ISIET 2019)

Social evening
Join us for the social evening in a typical rustic location, the “Meiers Lebenslust” in the city of Hanover.

Do not miss this great opportunity for mutual exchange and enjoy a freshly brewed beer from the craft brewery.

Date: Tuesday, 5 November
Time: from 20:00
Place: Meiers Lebenslust
Osterstrasse 64
30159 Hanover

Post conference tour INNER EAR LABS – guided tour through NIFE (Lower Saxony Centre for Biomedical Engineering, Implant Research and Development) for those who are interested, registration requested

Date: Wednesday, 6 November
Time: from 14:00–16:00 (meeting point 13:45)
Place: Conference office at the check-in
General information

General terms and conditions
Please find our general terms and conditions at www.isiet.org.

Certification
The conference will be certified by the “Landesärztekammer Niedersachsen” as well as by EACCME.

Proof of attendance
For certification you must provide proof of attendance. Therefore, please sign to the list at the check-in desk onsite every day at the conference.

Certificate of attendance
Certificates of attendance will only be made available on the last day of the conference/congress at the check-in desk.

Name badge
Please wear your name badge during all conference events, including the networking activities. Admission to scientific sessions and to the industrial exhibition is restricted to participants wearing their badge. Participants will receive their name badge when collecting their conference documents at the check-in desk.

WIFI access
WIFI is available for free throughout the whole conference area. Please ask at the check-in desk for the login data.
**Submission of a presentation/Technical information**

Your Presentation should be prepared as PDF- or PowerPoint (Office 2016) with (4:3) aspect ratio. For video- and audiofiles, please use standard formats (AVI, WMV, MPG) and bring these as separate files to the speakers’ ready room. When using videos, please remember to include the required Codec. The use of personal notebooks is possible upon agreement. Please provide an adapter for HDMI (VGA) if necessary.

A technical assistant will support you.

Should you wish to use non-digital equipment, please contact us in advance.

**Time allocation**

Please prepare your presentation for the allotted amount of time. Chairs and moderators may interrupt should you overrun your time limit.

**Poster session**

Your poster must be in English, DIN A0 (84,1 cm x 118,9 cm) and of vertical format. Pins will be provided on your poster board. Please do not use any other type of pins than those provided. All poster boards will be labelled with a poster number. You can find your poster number in the programme book. Please note that all posters should be hung by Monday 10:00 and be removed at the latest by Wednesday 13:00. Posters that have not been removed by the stated time will be considered as waste.
### INDEX OF SPEAKERS, PRESENTING AUTHORS AND CHAIRS

<p>| A | Ahmadi, N. | 9, 17 |
|   | Anderson, C. | 17 |
|   | Ardiç, F. | 19 |
|   | Avraham, K. B. | 11, 18 |
| B | Büning, H. | 6, 12 |
|   | Burns, J. | 13 |
| C | Calvet, C. | 13 |
|   | Chen, Z.-Y. | 12 |
|   | Chien, W. | 18 |
| D | de Vrieze, E. | 12 |
| E | Ernst, B. P. | 14 |
| F | Fetoni, A. R. | 17 |
|   | Fink, S. | 15 |
|   | Fuentes, D. B. B. | 20 |
| G | Gimona, M. | 6 |
|   | Grimm, D. | 15 |
|   | Gröschel, M. | 16 |
|   | Gubbels, S. | 19 |
|   | Gui, F. | 19 |
| H | Hashino, E. | 11 |
|   | Haverich, A. | 6 |
|   | Holt, J. | 12 |
|   | Honeder, C. | 9, 17 |
|   | Housley, G. | 11 |
|   | Hsu, Y.-C. | 15 |
| I | Illig, T. | 8 |
| J | Juiz, J. M. | 18 |
| K | Kil, J. | 7 |
|   | Knipper, M. | 7 |
|   | Konerdning, W. | 14 |
|   | Korotkova, V. | 18 |
| L | Langguth, B. | 12 |
|   | Lanting, C. | 8, 14 |
|   | Laurell, G. | 9 |
|   | LeBel, C. | 10 |
|   | Lemesre, P. E. | 14, 17 |
|   | Lenarz, T. | 6, 11, 19, 20, 21 |
|   | Lesinski-Schiedat, A. | 8 |
|   | Lewis, E. | 11 |
|   | Lewis, M. | 12 |
|   | Lustig, L. R. | 12 |
| M | Mandavia, R. | 8, 19 |
|   | Martelletti, E. | 7 |
|   | Mazurek, B. | 13, 14 |
|   | McLean, W. | 10 |
|   | Mehta, N. | 8 |
| N | Nishio, S.-Y. | 8 |
|   | Nuss, W. | 20 |
| P | Pawley, D. | 9, 17 |
|   | Pennings, R. | 8, 14 |
|   | Perez Raffo, G. | 15 |
|   | Petit, C. | 7, 13 |
|   | Piu, F. | 9 |
|   | Ploite, S. | 15 |
|   | Prenzler, N. | 9 |
| Q | Qnouch, A. | 9, 17 |</p>
<table>
<thead>
<tr>
<th>Speaker</th>
<th>Page References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raible, D.</td>
<td>16</td>
</tr>
<tr>
<td>Raji, A.</td>
<td>11</td>
</tr>
<tr>
<td>Rajput, K.</td>
<td>16</td>
</tr>
<tr>
<td>Rankovic, V.</td>
<td>11</td>
</tr>
<tr>
<td>Raumane, D.</td>
<td>20</td>
</tr>
<tr>
<td>Risoud, M.</td>
<td>14, 17</td>
</tr>
<tr>
<td>Rohde, E.</td>
<td>6</td>
</tr>
<tr>
<td>Safieddine, S.</td>
<td>13</td>
</tr>
<tr>
<td>Salcher, R.</td>
<td>16</td>
</tr>
<tr>
<td>Schambach, A.</td>
<td>12, 15</td>
</tr>
<tr>
<td>Scheper, V.</td>
<td>17</td>
</tr>
<tr>
<td>Schilder, A. G. M.</td>
<td>8, 16, 17, 19</td>
</tr>
<tr>
<td>Schulze, J.</td>
<td>17, 19</td>
</tr>
<tr>
<td>Schwieger, J.</td>
<td>20</td>
</tr>
<tr>
<td>Segil, N.</td>
<td>13</td>
</tr>
<tr>
<td>Sethukumar, P.</td>
<td>8</td>
</tr>
<tr>
<td>Shu, Y.</td>
<td>18</td>
</tr>
<tr>
<td>Song, L.</td>
<td>13, 14</td>
</tr>
<tr>
<td>Staecker, H.</td>
<td>11, 19</td>
</tr>
<tr>
<td>Steyger, P.</td>
<td>6, 19</td>
</tr>
<tr>
<td>Szczepke, A.</td>
<td>6</td>
</tr>
<tr>
<td>Taiber, S.</td>
<td>18</td>
</tr>
<tr>
<td>Tao, Y.</td>
<td>12</td>
</tr>
<tr>
<td>Telischi, F. F.</td>
<td>9, 17</td>
</tr>
<tr>
<td>Thum, T.</td>
<td>7</td>
</tr>
<tr>
<td>van Rompaey, V.</td>
<td>7</td>
</tr>
<tr>
<td>Versnel, H.</td>
<td>18, 20</td>
</tr>
<tr>
<td>Warnecke, A.</td>
<td>6, 16, 17, 19, 20</td>
</tr>
<tr>
<td>Wilden, L.</td>
<td>11</td>
</tr>
<tr>
<td>Wille, I.</td>
<td>17</td>
</tr>
<tr>
<td>Wrobel, C.</td>
<td>20</td>
</tr>
<tr>
<td>Xiong, W.</td>
<td>13</td>
</tr>
<tr>
<td>Yadak, R.</td>
<td>18</td>
</tr>
<tr>
<td>Yildirim, O.</td>
<td>8, 19</td>
</tr>
<tr>
<td>Zeltes, T.</td>
<td>20</td>
</tr>
<tr>
<td>Zine, A.</td>
<td>7</td>
</tr>
</tbody>
</table>
As a full-service PCO, we provide you with intelligent and innovative solutions in an advisory and implementing manner.
Sensorion is pleased to sponsor the 2nd International Symposium on Inner Ear Therapeutics

4-6 November 2019
Hanover, Germany
Eliminating Hearing Loss as a Chronic Condition.

Rescue Hearing INC has assembled a group of visionary, internationally recognized physicians, scientists and bio engineers who share a common passion for developing therapies for humans suffering from hearing loss. The team is developing therapeutic and diagnostic platforms that will address the most difficult of hearing loss indications.

Hearing loss affects half of all octogenarians and is diagnosed in 3 in 1,000 newborns.

For more information: rescuehearing.com
Breakthrough Tinnitus Treatment

Convenient and easy to use, Lenire® can provide sustainable relief from tinnitus.

For more information visit: lenire.com
A practical overview of a promising technology

Robotic Surgery

Editors
Asit Arora
Luke Cascarini
Jean-Pierre Jeannon

Contents

Review Articles
• Transoral Robotic Surgery for Obstructive Sleep Apnoea-Hypopnoea Syndrome: Vauterin, T.; Arora, A., Garas, G.
• Transoral Robotic Surgery for Oropharyngeal Cancer: Paleri, V.; Fox, H.; Winter, S.
• Robotic Thyroid Surgery: Current Perspectives and Future Considerations: Aidan, P.; Arora, A.; Lorincz, B.; Tolley, N.; Garas, G.
• Robotic Parathyroid Surgery: Current Perspectives and Future Considerations: Arora, A.; Garas, G.; Tolley, N.
• Transoral Robotic Surgery: Image Guidance and Augmented Reality: Pratt, P.; Arora, A.

Original Paper
• Anaesthesia and Perioperative Care for Transoral Robotic Surgery: Jeyarajah, J.; Ahmad, I.; Jacovou, E.
• Transoral Robotic Surgery Total Laryngectomy: Lawson, G.; Mendelsohn, A.; Fakhoury, R.; Van der Vorst, S.; Remacle, M.; Bachy, V.; Delahaut, G.

Research Article
The smallest-ever CI sound processor

As the smallest-ever CI sound processor on the market, the elegant Neuro 2 is about discretion. But it’s so much more than just its size. Combining great sound quality and a wealth of innovative features and accessories for all ages and lifestyles, its design has already won a number of awards.

All aspects of the Neuro 2 have been designed to meet the highest standards. Whether it’s the transparent ultra-strong aramid reinforced cable, or the IP68 ranking – the highest protection against dust and water in the CI industry – reached without extra accessories, Neuro 2 is designed to give you hearing confidence all day, every day.

www.oticonmedical.com/Neuro2